Literature DB >> 1535910

Non-Hodgkin lymphoma in the porta hepatis after orthotopic liver transplantation: sonographic findings.

A R Moody1, S R Wilson, P D Greig.   

Abstract

The sonographic appearances of primary non-Hodgkin lymphoma developing in the porta hepatis in three patients soon after hepatic transplantation were reviewed. The lymphomas appeared as large hypoechoic masses encasing vital portal structures--the hepatic artery and the common bile duct--in all three cases and displacing the portal vein in two. The liver was only locally involved. All patients presented with jaundice soon after transplantation (average interval, 6.3 months). Rapid tumor progression caused hepatic infarction, necessitating retransplantation in two patients. The third patient died shortly after diagnosis. The authors believe this complication will be seen increasingly as liver transplantation becomes more common. Non-Hodgkin lymphoma should be considered when an obstructing mass is found in the porta hepatis, even when the time interval since transplantation is short.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1535910     DOI: 10.1148/radiology.182.3.1535910

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

1.  Diffuse large B-cell lymphoma with tumor thrombosis in the portal vein.

Authors:  Nobuhiro Kanemura; Hisashi Tsurumi; Toshiki Yamada; Yasushi Kojima; Senji Kasahara; Hisataka Moriwaki
Journal:  Int J Hematol       Date:  2006-10       Impact factor: 2.490

2.  Primary malignant lymphoma in the porta hepatis: a case report.

Authors:  H Irie; H Honda; K Kaneko; T Kuroiwa; T Fukuya; K Yoshimitsu; H Aibe; K Masuda
Journal:  Abdom Imaging       Date:  1996 Sep-Oct

3.  Percutaneous transhepatic stenting by Wallstents of portal vein and bile duct stenoses caused by immunoblastic sarcoma in a liver transplantation.

Authors:  J I Bilbao; M Ruza; J M Longo; F Mansilla; A Picardi; V de Villa; F Pardo; J Sola; J Quiroga
Journal:  Cardiovasc Intervent Radiol       Date:  1994 Jul-Aug       Impact factor: 2.740

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.